Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Disis, Mary L., Wallace, Danelle R., Gooley, Theodore A., Dang, Yushe, Slota, Meredith, Lu, Hailing, Coveler, Andrew L., Childs, Jennifer S., Higgins, Doreen M., Fintak, Patricia A., dela Rosa, Corazon, Tietje, Kathleen, Link, John, Waisman, James, Salazar, Lupe G.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754913/
https://ncbi.nlm.nih.gov/pubmed/19720923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6789
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars